Ocular Therapeutix is a privately held Bedford, Massachusetts company focused on developing and commercializing ophthalmic therapeutic products built on proprietary hydrogel technology. Its pipeline includes drug-eluting punctum plugs for glaucoma and post-operative inflammation and pain, injectable depots for back-of-the-eye diseases, and the ReSure Sealant for sealing clear corneal incisions. The company is advancing sustained-release drug programs, including prostaglandin analogs for glaucoma and corticosteroids for post-operative inflammation and pain. Recent financing will support further development of these sustained-release programs and the planned commercial launch of ReSure in the United States following FDA approval. Financially, Ocular secured additional financing in which Baxter Ventures acquired a minority equity stake; Ascension Health Ventures, which led the Series D, also participated. The financing follows a Series D extension that closed in November 2012. Ocular Therapeutix develops and commercializes ophthalmic therapeutic products built on a proprietary hydrogel platform. Its pipeline includes drug-eluting punctum plugs for glaucoma and post-operative inflammation and pain, injectable depots for back-of-the-eye diseases, and the ReSure® Sealant for sealing corneal incisions. The company is advancing sustained-release drug programs intended to improve patient compliance and drug safety by avoiding peaks and valleys of topical administration. Current development priorities named in the articles include travoprost for glaucoma and dexamethasone for resolution of post-operative inflammation and pain. Ocular Therapeutix also plans to support U.S. commercial launch efforts and to develop sustained-release therapies for retinal diseases in collaboration with pharmaceutical partners. The company is privately held and based in Bedford, Massachusetts. Ocular Therapeutix develops and commercializes ophthalmic therapeutic products using a proprietary hydrogel technology. Its first product, the ReSure Adherent Ocular Bandage, is CE Mark approved and commercially available outside the United States. The company closed a $14M Series D financing and intends to use the proceeds to conduct Phase II clinical trials across multiple therapeutic areas. The initial trial will reinforce safety and test efficacy of a moxifloxacin-loaded punctum plug; subsequent Phase II studies are planned for punctum plugs targeting glaucoma, dry eye, and allergies. Founded in November 2006, Ocular Therapeutix is led by President and CEO Amar Sawhney and is based in Bedford, Massachusetts.

Total raised

$38M

Funding rounds

3

Latest round

Series D

Latest activity

Jan 2013